UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Liver international, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 47 - 57
ledipasvir | sofosbuvir | dasabuvir grazoprevir | ombitasvir | velpatasvir | elbasvir | paritaprevir | Ombitasvir | Dasabuvir grazoprevir | Ledipasvir | Paritaprevir | Elbasvir | Velpatasvir | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Sofosbuvir - therapeutic use | Anilides - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Humans | Fluorenes - therapeutic use | Cyclopropanes | Hepacivirus - genetics | Uracil - therapeutic use | Amides | Genotype | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Sulfonamides - therapeutic use | Female | Imidazoles - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Uracil - analogs & derivatives | Virus diseases | Protease inhibitors | Proteases | Interferon | Drug therapy | Hepatitis C virus | Health aspects | Index Medicus
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Journal of hepatology, ISSN 0168-8278, 09/2019, Volume 71, Issue 3, pp. 486 - 497
Treatment | Sleep | Pain | Liver | Patient-reported outcome | HCV | PRO | Symptom | Quality of life | Functioning | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Benzimidazoles | Prospective Studies | Humans | Middle Aged | Fluorenes | Hepatitis C, Chronic - virology | Male | Cyclopropanes - therapeutic use | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Patient Reported Outcome Measures | Quinoxalines - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Amides - therapeutic use | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Uracil - analogs & derivatives | Mental disorders | Ritonavir | Mental health | Chronic infection | Fatigue | Regression analysis | Patients | Cirrhosis | Hepatitis | Minimum inhibitory concentration | Hepatitis C | Index Medicus | sleep | treatment | functioning | pain | symptom | liver | patient-reported outcome | quality of life
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | Biological and medical sciences | General aspects | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | Biological and medical sciences | General aspects | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | RNA, Viral - isolation & purification | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Retreatment | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Ritonavir | Infections | RNA polymerase | Pruritus | Patients | Ribavirin | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Head & neck, ISSN 1043-3074, 05/2012, Volume 34, Issue 5, pp. 736 - 745
epidermal growth factor (EGF) | RET | immunomodulator | vascular disrupting agent | multi‐kinase inhibitor | vascular endothelial growth factor (VEGF) | thyroid cancer | histone acetylation | B‐Raf | heat shock protein (HSP) | multi-kinase inhibitor | B-Raf | Otorhinolaryngology | Life Sciences & Biomedicine | Surgery | Science & Technology | Otorhinolaryngology. Stomatology | Malignant tumors | Pharmacology. Drug treatments | Thyroid. Thyroid axis (diseases) | Biological and medical sciences | Endocrinopathies | Medical sciences | Immunomodulators | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bibenzyls - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Valproic Acid - therapeutic use | Depsipeptides - therapeutic use | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Pyrroles - therapeutic use | Pyridines - therapeutic use | Bortezomib | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Benzamides | Thalidomide - therapeutic use | Benzoquinones - therapeutic use | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article